Indoco Remedies Management Meet Update - Outlook Remains Strong: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
We recently hosted the management of Indoco Remedies Ltd. to discuss the company’s business as it stands and future prospects. The key takeaways from our discussion are as follows-
Indoco Remedies is focusing on improving execution in Northern and Eastern markets in India as medical representatives’ productivity remains low in these areas. Northern and Western markets also have higher penetration of acute drugs, which is an area of strength for the company.
In the U.S. market, the growth trajectory should sustain as it has launches lined up that include a limited competition product by the end of Q4 FY22.
Launches in partnership with Teva should happen about 14 months from now.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.